Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2012

Open Access 01-04-2012 | Research article

Cytokines profiling by multiplex analysis in experimental arthritis: which pathophysiological relevance for articular versus systemic mediators?

Authors: Joseph Paquet, Jean-Christophe Goebel, Camille Delaunay, Astrid Pinzano, Laurent Grossin, Christel Cournil-Henrionnet, Pierre Gillet, Patrick Netter, Jean-Yves Jouzeau, David Moulin

Published in: Arthritis Research & Therapy | Issue 2/2012

Login to get access

Abstract

Introduction

We have taken advantage of the large screening capacity of a multiplex immunoassay to better define the respective contribution of articular versus systemic cytokines in experimental arthritis.

Methods

We performed a follow up (from 7 hours to 14 days) multiplex analysis of 24 cytokines in synovial fluid and sera of rats developing Antigen-Induced Arthritis (AIA) and confronted their protein level changes with molecular, biochemical, histological and clinical events occurring in the course of the disease.

Results

The time-scheduled findings in arthritic joints correlated with time-dependent changes of cytokine amounts in joint effusions but not with their blood levels. From seven hours after sensitization, high levels of chemokines (MCP-1, MIP1α, GRO/KC, RANTES, eotaxin) were found in synovial fluid of arthritic knees whereas perivascular infiltration occurred in the synovium; local release of inflammatory cytokines (IFNγ, IL-1β, IL-6) preceded the spreading of inflammation and resulted in progressive degradation of cartilage and bone. Finally a local overexpression of several cytokines/adipocytokines poorly described in arthritis (IL-13, IL-18, leptin) was observed.

Conclusions

Distinct panels of cytokines were found in arthritic fluid during AIA, and the expected effect of mediators correlated well with changes occurring in joint tissues. Moreover, multiplex analysis could be helpful to identify new pathogenic mediators and to elucidate the mechanisms supporting the efficacy of putative targeted therapies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gorman CL, Cope AP: Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol. 2008, 22: 221-238. 10.1016/j.berh.2008.01.003.CrossRef Gorman CL, Cope AP: Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol. 2008, 22: 221-238. 10.1016/j.berh.2008.01.003.CrossRef
2.
go back to reference Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, Imhof BA, Koch AE: Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum. 2008, 58: 3020-3029. 10.1002/art.23867.CrossRef Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, Imhof BA, Koch AE: Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum. 2008, 58: 3020-3029. 10.1002/art.23867.CrossRef
3.
go back to reference Pundt N, Peters MA, Wunrau C, Pap T: Gene therapy in rheumatoid arthritis: new aspects [in German]. Dtsch Med Wochenschr. 2008, 133: 1737-1741. 10.1055/s-0028-1082797.CrossRef Pundt N, Peters MA, Wunrau C, Pap T: Gene therapy in rheumatoid arthritis: new aspects [in German]. Dtsch Med Wochenschr. 2008, 133: 1737-1741. 10.1055/s-0028-1082797.CrossRef
4.
go back to reference Andreas K, Lubke C, Haupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M: Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008, 10:R9: 1-16. Andreas K, Lubke C, Haupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M: Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008, 10:R9: 1-16.
5.
go back to reference Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003, 2: 473-488. 10.1038/nrd1109.CrossRef Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003, 2: 473-488. 10.1038/nrd1109.CrossRef
6.
go back to reference Park JY, Pillinger MH: Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65 (Suppl 1): S4-10. Park JY, Pillinger MH: Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65 (Suppl 1): S4-10.
7.
go back to reference Fonseca JE, Santos MJ, Canhao H, Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009, 8: 538-542. 10.1016/j.autrev.2009.01.012.CrossRef Fonseca JE, Santos MJ, Canhao H, Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009, 8: 538-542. 10.1016/j.autrev.2009.01.012.CrossRef
8.
go back to reference Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-916. 10.1056/NEJM200103223441207.CrossRef Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-916. 10.1056/NEJM200103223441207.CrossRef
9.
go back to reference Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G: TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA. 2007, 104: 11742-11747. 10.1073/pnas.0610812104.CrossRef Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G: TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA. 2007, 104: 11742-11747. 10.1073/pnas.0610812104.CrossRef
10.
go back to reference Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman D, Jorgensen C, Apparailly F: Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008, 58: 2356-2367. 10.1002/art.23660.CrossRef Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman D, Jorgensen C, Apparailly F: Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008, 58: 2356-2367. 10.1002/art.23660.CrossRef
11.
go back to reference Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum. 2008, 58: S110-122.CrossRef Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum. 2008, 58: S110-122.CrossRef
12.
go back to reference Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004, 18: 59-80. 10.1016/j.berh.2003.09.010.CrossRef Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004, 18: 59-80. 10.1016/j.berh.2003.09.010.CrossRef
13.
go back to reference Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G: Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009, 68: 1171-1176. 10.1136/ard.2008.091264.CrossRef Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G: Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009, 68: 1171-1176. 10.1136/ard.2008.091264.CrossRef
14.
go back to reference Furst DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010, 39: 327-346. 10.1016/j.semarthrit.2008.10.002.CrossRef Furst DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010, 39: 327-346. 10.1016/j.semarthrit.2008.10.002.CrossRef
15.
go back to reference Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J: A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom. 2009, 76: 159-168.CrossRef Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J: A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom. 2009, 76: 159-168.CrossRef
16.
go back to reference Buchner E, Brauer R, Schmidt C, Emmrich F, Kinne RW: Induction of flare-up reactions in rat antigen-induced arthritis. J Autoimmun. 1995, 8: 61-74. Buchner E, Brauer R, Schmidt C, Emmrich F, Kinne RW: Induction of flare-up reactions in rat antigen-induced arthritis. J Autoimmun. 1995, 8: 61-74.
17.
go back to reference Griffiths RJ: Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Agents Actions. 1992, 35: 88-95. 10.1007/BF01990957.CrossRef Griffiths RJ: Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Agents Actions. 1992, 35: 88-95. 10.1007/BF01990957.CrossRef
18.
go back to reference Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006, 54: 1122-1131. 10.1002/art.21749.CrossRef Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006, 54: 1122-1131. 10.1002/art.21749.CrossRef
19.
go back to reference Pohlers D, Siegling A, Buchner E, Schmidt-Weber CB, Palombo-Kinne E, Emmrich F, Brauer R, Kinne RW: Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther. 2005, 7: R445-457. 10.1186/ar1689.CrossRef Pohlers D, Siegling A, Buchner E, Schmidt-Weber CB, Palombo-Kinne E, Emmrich F, Brauer R, Kinne RW: Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther. 2005, 7: R445-457. 10.1186/ar1689.CrossRef
20.
go back to reference Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Kenneth Haines G, Kunkel SL, Burdick MD, Koch AE: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. 2000, 43: 1266-1277. 10.1002/1529-0131(200006)43:6<1266::AID-ANR9>3.0.CO;2-P.CrossRef Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Kenneth Haines G, Kunkel SL, Burdick MD, Koch AE: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. 2000, 43: 1266-1277. 10.1002/1529-0131(200006)43:6<1266::AID-ANR9>3.0.CO;2-P.CrossRef
21.
go back to reference Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF: Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol. 2004, 137: 65-73. 10.1111/j.1365-2249.2004.02499.x.CrossRef Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF: Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol. 2004, 137: 65-73. 10.1111/j.1365-2249.2004.02499.x.CrossRef
22.
go back to reference Bolon B, Campagnuolo G, Zhu L, Duryea D, Zack D, Feige U: Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet Pathol. 2004, 41: 235-243. 10.1354/vp.41-3-235.CrossRef Bolon B, Campagnuolo G, Zhu L, Duryea D, Zack D, Feige U: Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet Pathol. 2004, 41: 235-243. 10.1354/vp.41-3-235.CrossRef
23.
go back to reference McDougall JJ, Watkins L, Li Z: Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain. 2006, 123: 98-105. 10.1016/j.pain.2006.02.015.CrossRef McDougall JJ, Watkins L, Li Z: Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain. 2006, 123: 98-105. 10.1016/j.pain.2006.02.015.CrossRef
24.
go back to reference Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B: Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 1988, 31: 956-963. 10.1002/art.1780310803.CrossRef Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B: Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 1988, 31: 956-963. 10.1002/art.1780310803.CrossRef
25.
go back to reference Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M: Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: 584-592. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M: Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: 584-592.
26.
go back to reference Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, Eberl H, Klause U, Robinson WH: Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther. 2011, 13: R102-10.1186/ar3383.CrossRef Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, Eberl H, Klause U, Robinson WH: Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther. 2011, 13: R102-10.1186/ar3383.CrossRef
27.
go back to reference Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B: Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum. 1999, 42: 2094-2102. 10.1002/1529-0131(199910)42:10<2094::AID-ANR9>3.0.CO;2-Y.CrossRef Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B: Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum. 1999, 42: 2094-2102. 10.1002/1529-0131(199910)42:10<2094::AID-ANR9>3.0.CO;2-Y.CrossRef
28.
go back to reference Grossin L, Cournil-Henrionnet C, Pinzano A, Gaborit N, Dumas D, Etienne S, Stoltz JF, Terlain B, Netter P, Mir LM, Gillet P: Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. Faseb J. 2006, 20: 65-75. 10.1096/fj.04-2889com.CrossRef Grossin L, Cournil-Henrionnet C, Pinzano A, Gaborit N, Dumas D, Etienne S, Stoltz JF, Terlain B, Netter P, Mir LM, Gillet P: Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. Faseb J. 2006, 20: 65-75. 10.1096/fj.04-2889com.CrossRef
29.
go back to reference Tonussi CR, Ferreira SH: Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain. 1992, 48: 421-427. 10.1016/0304-3959(92)90095-S.CrossRef Tonussi CR, Ferreira SH: Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain. 1992, 48: 421-427. 10.1016/0304-3959(92)90095-S.CrossRef
30.
go back to reference Tonussi CR, Ferreira SH: Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain. 1999, 82: 81-87. 10.1016/S0304-3959(99)00035-4.CrossRef Tonussi CR, Ferreira SH: Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain. 1999, 82: 81-87. 10.1016/S0304-3959(99)00035-4.CrossRef
31.
go back to reference Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009, 27: 519-550. 10.1146/annurev.immunol.021908.132612.CrossRef Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009, 27: 519-550. 10.1146/annurev.immunol.021908.132612.CrossRef
32.
go back to reference Pessler F, Mayer CT, Jung SM, Behrens EM, Dai L, Menetski JP, Schumacher HR: Identification of novel monosodium urate crystal regulated mRNAs by transcript profiling of dissected murine air pouch membranes. Arthritis Res Ther. 2008, 10: R64-10.1186/ar2435.CrossRef Pessler F, Mayer CT, Jung SM, Behrens EM, Dai L, Menetski JP, Schumacher HR: Identification of novel monosodium urate crystal regulated mRNAs by transcript profiling of dissected murine air pouch membranes. Arthritis Res Ther. 2008, 10: R64-10.1186/ar2435.CrossRef
33.
go back to reference Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RL, Crumrine RC, Leenitzer MA, McDougald DL, Han B, Hedeen K, Lin P, Milla M, Moss M, Pink H, Rabinowitz MH, Tippin T, Scates PW, Selph J, Stimpson SA, Warner J, Becherer JD: Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther. 2001, 298: 900-908. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RL, Crumrine RC, Leenitzer MA, McDougald DL, Han B, Hedeen K, Lin P, Milla M, Moss M, Pink H, Rabinowitz MH, Tippin T, Scates PW, Selph J, Stimpson SA, Warner J, Becherer JD: Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther. 2001, 298: 900-908.
34.
go back to reference Fujisawa T, Igeta K, Odake S, Morita Y, Yasuda J, Morikawa T: Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg Med Chem. 2002, 10: 2569-2581. 10.1016/S0968-0896(02)00109-8.CrossRef Fujisawa T, Igeta K, Odake S, Morita Y, Yasuda J, Morikawa T: Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg Med Chem. 2002, 10: 2569-2581. 10.1016/S0968-0896(02)00109-8.CrossRef
35.
go back to reference Deffaud J, Kirchmeyer M, Domagala F, Ficheux H, Netter P, Bianchi A, Jouzeau JY: Modulatory effect of rhein on IL-1alpha-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs. Biorheology. 2008, 45: 439-455. Deffaud J, Kirchmeyer M, Domagala F, Ficheux H, Netter P, Bianchi A, Jouzeau JY: Modulatory effect of rhein on IL-1alpha-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs. Biorheology. 2008, 45: 439-455.
36.
go back to reference De Ceuninck F, Dassencourt L, Anract P: The inflammatory side of human chondrocytes unveiled by antibody microarrays. Biochem Biophys Res Commun. 2004, 323: 960-969. 10.1016/j.bbrc.2004.08.184.CrossRef De Ceuninck F, Dassencourt L, Anract P: The inflammatory side of human chondrocytes unveiled by antibody microarrays. Biochem Biophys Res Commun. 2004, 323: 960-969. 10.1016/j.bbrc.2004.08.184.CrossRef
37.
go back to reference Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.
38.
go back to reference Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J: Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006, 24: 529-533. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J: Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006, 24: 529-533.
39.
go back to reference Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M: Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008, 31: 175-179. 10.1016/j.jaut.2008.07.002.CrossRef Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M: Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008, 31: 175-179. 10.1016/j.jaut.2008.07.002.CrossRef
40.
go back to reference Petrovic-Rackov L: Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid [in Serbian]. Vojnosanit Pregl. 2006, 63: 21-26. 10.2298/VSP0601021P.CrossRef Petrovic-Rackov L: Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid [in Serbian]. Vojnosanit Pregl. 2006, 63: 21-26. 10.2298/VSP0601021P.CrossRef
41.
go back to reference Leisten JC, Gaarde WA, Scholz W: Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin. Clin Immunol Immunopathol. 1990, 56: 108-115. 10.1016/0090-1229(90)90174-O.CrossRef Leisten JC, Gaarde WA, Scholz W: Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin. Clin Immunol Immunopathol. 1990, 56: 108-115. 10.1016/0090-1229(90)90174-O.CrossRef
42.
go back to reference Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M: Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005, 7: R784-795. 10.1186/ar1733.CrossRef Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M: Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005, 7: R784-795. 10.1186/ar1733.CrossRef
43.
go back to reference Punzi L, Calo L, Plebani M: Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci. 2002, 39: 63-88. 10.1080/10408360290795448.CrossRef Punzi L, Calo L, Plebani M: Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci. 2002, 39: 63-88. 10.1080/10408360290795448.CrossRef
44.
go back to reference Bendele A: Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001, 1: 377-385. Bendele A: Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001, 1: 377-385.
45.
go back to reference Krohn KD, Brandt KD, Braunstein E, Mathews V: Hereditary symphalangism. Association with osteoarthritis. J Rheumatol. 1989, 16: 977-982. Krohn KD, Brandt KD, Braunstein E, Mathews V: Hereditary symphalangism. Association with osteoarthritis. J Rheumatol. 1989, 16: 977-982.
46.
go back to reference Conti P, Reale M, Barbacane RC, Castellani ML, Orso C: Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. Immunol Lett. 2002, 80: 105-111. 10.1016/S0165-2478(01)00303-0.CrossRef Conti P, Reale M, Barbacane RC, Castellani ML, Orso C: Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. Immunol Lett. 2002, 80: 105-111. 10.1016/S0165-2478(01)00303-0.CrossRef
47.
go back to reference Menten P, Wuyts A, Van Damme J: Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002, 13: 455-481. 10.1016/S1359-6101(02)00045-X.CrossRef Menten P, Wuyts A, Van Damme J: Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002, 13: 455-481. 10.1016/S1359-6101(02)00045-X.CrossRef
48.
go back to reference Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996, 97: 604-612. 10.1172/JCI118456.CrossRef Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996, 97: 604-612. 10.1172/JCI118456.CrossRef
49.
go back to reference Syversen SW, Goll GL, Haavardsholm EA, Boyesen P, Lea T, Kvien TK: A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R28-10.1186/ar2381.CrossRef Syversen SW, Goll GL, Haavardsholm EA, Boyesen P, Lea T, Kvien TK: A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R28-10.1186/ar2381.CrossRef
50.
go back to reference Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 1999, 42: 1109-1118. 10.1002/1529-0131(199906)42:6<1109::AID-ANR7>3.0.CO;2-7.CrossRef Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 1999, 42: 1109-1118. 10.1002/1529-0131(199906)42:6<1109::AID-ANR7>3.0.CO;2-7.CrossRef
51.
go back to reference Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, Horuk R, Perez HD: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest. 1998, 101: 2910-2919. 10.1172/JCI2172.CrossRef Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, Horuk R, Perez HD: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest. 1998, 101: 2910-2919. 10.1172/JCI2172.CrossRef
52.
go back to reference Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, Haas CS, Pope RM, Haines GK, Zha YY, Koch AE: Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005, 52: 1907-1919. 10.1002/art.21033.CrossRef Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, Haas CS, Pope RM, Haines GK, Zha YY, Koch AE: Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005, 52: 1907-1919. 10.1002/art.21033.CrossRef
53.
go back to reference Tetlow LC, Woolley DE: Eosinophils are an insignificant cellular component of rheumatoid synovium in patients with late stage disease: comparative distributions with mast cells and macrophages. Ann Rheum Dis. 1996, 55: 548-551. 10.1136/ard.55.8.548.CrossRef Tetlow LC, Woolley DE: Eosinophils are an insignificant cellular component of rheumatoid synovium in patients with late stage disease: comparative distributions with mast cells and macrophages. Ann Rheum Dis. 1996, 55: 548-551. 10.1136/ard.55.8.548.CrossRef
54.
go back to reference Bockermann R, Holmdahl R: Type II collagen without adjuvant induces eosinophilic arthritis. Eur J Immunol. 2007, 37: 540-548. 10.1002/eji.200636191.CrossRef Bockermann R, Holmdahl R: Type II collagen without adjuvant induces eosinophilic arthritis. Eur J Immunol. 2007, 37: 540-548. 10.1002/eji.200636191.CrossRef
55.
go back to reference Cook DN: The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol. 1996, 59: 61-66. Cook DN: The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol. 1996, 59: 61-66.
56.
go back to reference Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Rivo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A: Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine. 2008, 44: 191-200. 10.1016/j.cyto.2008.08.002.CrossRef Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Rivo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A: Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine. 2008, 44: 191-200. 10.1016/j.cyto.2008.08.002.CrossRef
57.
go back to reference Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG: Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 2008, 58: 2368-2378. 10.1002/art.23608.CrossRef Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG: Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 2008, 58: 2368-2378. 10.1002/art.23608.CrossRef
58.
go back to reference Herman S, Kronke G, Schett G: Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med. 2008, 14: 245-253. 10.1016/j.molmed.2008.04.001.CrossRef Herman S, Kronke G, Schett G: Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med. 2008, 14: 245-253. 10.1016/j.molmed.2008.04.001.CrossRef
59.
go back to reference Matsui K, Tsutsui H, Nakanishi K: Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets. 2003, 7: 701-724. 10.1517/14728222.7.6.701.CrossRef Matsui K, Tsutsui H, Nakanishi K: Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets. 2003, 7: 701-724. 10.1517/14728222.7.6.701.CrossRef
60.
go back to reference Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N: Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol Int. 2008, 57: 367-376. 10.2332/allergolint.O-08-546.CrossRef Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N: Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol Int. 2008, 57: 367-376. 10.2332/allergolint.O-08-546.CrossRef
61.
go back to reference Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M: Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 2008, 126: 386-393.CrossRef Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M: Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 2008, 126: 386-393.CrossRef
62.
go back to reference Lubberts E, Koenders MI, van den Berg WB: The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005, 7: 29-37. 10.1186/ar1478.CrossRef Lubberts E, Koenders MI, van den Berg WB: The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005, 7: 29-37. 10.1186/ar1478.CrossRef
63.
go back to reference Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004, 50: 650-659. 10.1002/art.20001.CrossRef Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004, 50: 650-659. 10.1002/art.20001.CrossRef
64.
go back to reference Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T: Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008, 58: 754-763. 10.1002/art.23222.CrossRef Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T: Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008, 58: 754-763. 10.1002/art.23222.CrossRef
65.
go back to reference Pacquelet S, Presle N, Boileau C, Dumond H, Netter P, Martel-Pelletier J, Pelletier JP, Terlain B, Jouzeau JY: Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J Rheumatol. 2002, 29: 2602-2610. Pacquelet S, Presle N, Boileau C, Dumond H, Netter P, Martel-Pelletier J, Pelletier JP, Terlain B, Jouzeau JY: Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J Rheumatol. 2002, 29: 2602-2610.
66.
go back to reference Nagy JA, Dvorak AM, Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007, 2: 251-275. 10.1146/annurev.pathol.2.010506.134925.CrossRef Nagy JA, Dvorak AM, Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007, 2: 251-275. 10.1146/annurev.pathol.2.010506.134925.CrossRef
67.
go back to reference Eyles JL, Roberts AW, Metcalf D, Wicks IP: Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006, 2: 500-510. 10.1038/ncprheum0291.CrossRef Eyles JL, Roberts AW, Metcalf D, Wicks IP: Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006, 2: 500-510. 10.1038/ncprheum0291.CrossRef
68.
go back to reference Fleetwood AJ, Cook AD, Hamilton JA: Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol. 2005, 25: 405-428. 10.1615/CritRevImmunol.v25.i5.50.CrossRef Fleetwood AJ, Cook AD, Hamilton JA: Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol. 2005, 25: 405-428. 10.1615/CritRevImmunol.v25.i5.50.CrossRef
69.
go back to reference Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O: Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008, 252: 139-145. 10.1016/j.cellimm.2007.09.004.CrossRef Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O: Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008, 252: 139-145. 10.1016/j.cellimm.2007.09.004.CrossRef
70.
go back to reference Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001, 194: 809-821. 10.1084/jem.194.6.809.CrossRef Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001, 194: 809-821. 10.1084/jem.194.6.809.CrossRef
71.
go back to reference Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME: Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA. 2008, 105: 7240-7245. 10.1073/pnas.0802465105.CrossRef Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME: Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA. 2008, 105: 7240-7245. 10.1073/pnas.0802465105.CrossRef
72.
go back to reference Renauld JC: Role of interleukin-9 in asthma and allergic reactions. Bull Mem Acad R Med Belg. 2007, 162: 275-282. Renauld JC: Role of interleukin-9 in asthma and allergic reactions. Bull Mem Acad R Med Belg. 2007, 162: 275-282.
73.
go back to reference Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008, 105: 10913-10918. 10.1073/pnas.0801898105.CrossRef Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008, 105: 10913-10918. 10.1073/pnas.0801898105.CrossRef
Metadata
Title
Cytokines profiling by multiplex analysis in experimental arthritis: which pathophysiological relevance for articular versus systemic mediators?
Authors
Joseph Paquet
Jean-Christophe Goebel
Camille Delaunay
Astrid Pinzano
Laurent Grossin
Christel Cournil-Henrionnet
Pierre Gillet
Patrick Netter
Jean-Yves Jouzeau
David Moulin
Publication date
01-04-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3774

Other articles of this Issue 2/2012

Arthritis Research & Therapy 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.